Selank Storage and Stability: What Studies Report

The short version of what the literature covers

The question people search most often — "how long does Selank last" — is usually asked about a vial rather than about a biological effect. The honest answer from the published record is that no dedicated stability or shelf-life study of Selank appears among the peer-reviewed papers indexed for this compound. The Selank literature is overwhelmingly pharmacological and clinical: rodent behaviour, cytokine profiles, gene expression, hepatocyte morphology, electrophysiology and one Russian clinical report. Those papers describe what the peptide did in an experimental system, not how long a solution of it remained intact on a bench or in a freezer.

That means anyone reading about "Selank shelf life" is almost always reading general peptide-chemistry principles, manufacturer documentation, or extrapolation from peptides of the same class — not a published accelerated-stability dataset for this molecule. This page separates those categories explicitly, because conflating them is the main source of confusion. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment.

What Selank is, chemically

Selank is a synthetic heptapeptide. Reviewers describing its molecular pharmacology have characterised it as a peptide-based anxiolytic built around the immunomodulatory fragment tuftsin, with the sequence extended by a stabilising tripeptide tail (PMID 30255741). Other researchers have likewise described it as a peptide analogue of tuftsin in work on morphine withdrawal signs in rats (PMID 36322304).

Three chemical features of a short peptide matter for stability discussions in general:

• Short chain length. A heptapeptide has no tertiary structure to lose, so the "denaturation" failure mode that dominates protein stability does not apply in the same way. Degradation of short peptides is generally chemical (bond hydrolysis, side-chain reactions) or physical (adsorption, aggregation) rather than conformational.
• Side-chain inventory. Selank's sequence contains no cysteine, methionine or tryptophan, the residues most associated with oxidation, and no asparagine or glutamine, the residues most associated with deamidation. Peptides lacking those residues are, as a class, discussed as less vulnerable to those two specific pathways — a general chemistry point, not a measured result for Selank.
• Proline content. The reviewers who mapped Selank's activity noted that the added tail was intended to improve stability relative to tuftsin itself (PMID 30255741). Proline-rich motifs are frequently described in peptide chemistry as resistant to several common peptidases, which is a biological-stability argument rather than a storage-stability measurement.

Lyophilized powder versus reconstituted solution

The single most consistent theme in general peptide-handling literature is that the dry state and the wet state behave very differently. Water is a reactant in peptide-bond hydrolysis, so removing it slows most chemical degradation routes dramatically. Lyophilized (freeze-dried) peptide is therefore the form in which research material is normally distributed and archived, while solutions are generally treated as short-lived working preparations.

The right-hand column is the point of the table. Every row in the middle column is textbook peptide handling; none of it has been measured and published for Selank in the papers available here.

Why "how long does a reconstituted solution last" has no citable number

A shelf-life figure is only meaningful when tied to a stated analytical method, an acceptance limit, a temperature, a concentration, a buffer and a container. Stability studies report those parameters — for example, percentage of intact peptide remaining by HPLC after a defined interval at a defined temperature. Because no such study for Selank appears in the indexed literature, any specific number circulating online is either taken from a supplier's internal document, borrowed from an unrelated peptide, or simply asserted. PeptideU does not reproduce numbers that cannot be traced to a published source.

Temperature

Temperature is the variable with the clearest theoretical basis. Chemical degradation rates generally fall as temperature falls, which is why cold-chain handling is standard for peptide reference material and why accelerated-stability testing deliberately uses elevated temperature to compress timelines. In practice, laboratory protocols distinguish three regimes: ambient (used for short working periods), refrigerated (used for in-use solutions), and frozen (used for archival storage of dry material or aliquots). None of the Selank studies cited on this page reported storage temperatures in their abstracts, so the compound's position within those regimes has to be inferred from class behaviour rather than quoted.

Freeze-thaw cycles

Freeze-thaw stress is routinely evaluated in formal stability programmes because freezing concentrates solutes in the unfrozen fraction, shifts local pH as buffer components crystallise at different rates, and creates ice-water interfaces where peptides can adsorb. For large proteins this can cause aggregation; for short peptides the more commonly discussed consequence is gradual loss of measurable material rather than structural damage. Aliquoting into single-use volumes is the standard laboratory answer to cycling, precisely so that a stock is thawed once. Again, no freeze-thaw dataset specific to Selank was located.

Light and container

Photostability testing is a formal part of pharmaceutical stability programmes, and light sensitivity in peptides is concentrated in residues with aromatic rings or sulphur atoms. Selank's sequence contains neither class of residue, which is why light is usually treated as a lower-priority variable for this molecule in general discussion — though, as with everything above, that is a prediction from structure rather than a published measurement.

Container effects are easier to underestimate. At the low concentrations typical of research peptide solutions, a non-trivial fraction of the peptide can adsorb to glass or polypropylene surfaces, which shows up as apparent potency loss even when the molecule itself is chemically intact. Stability literature addresses this with carrier proteins, surfactants, silanised glass or low-binding plastics, and it is one reason apparent "degradation" and actual degradation are treated as separate findings.

What the Selank studies themselves reported

Although none of the following papers were stability studies, they define what the compound was shown to do when freshly prepared material was used, and they are the reason storage questions are asked at all.

• In a behavioural model, researchers reported that Selank enhanced the anxiolytic effect of diazepam in rats exposed to unpredictable chronic mild stress (PMID 28280289). The study was a rodent pharmacology experiment and did not address preparation shelf life.
• A cell-based study reported that GABA, Selank and olanzapine each affected expression of genes involved in GABAergic neurotransmission in IMR-32 cells (PMID 28293190), and an electrophysiology study examined Selank's effect on spontaneous synaptic activity of rat hippocampal CA1 neurons (PMID 28361410).
• In alcohol-related models, researchers reported that Selank inhibited ethanol-induced hyperlocomotion and the manifestation of behavioural sensitisation in DBA/2 mice (PMID 27878720), and a separate rat study reported protection against ethanol-induced memory impairment with changes in BDNF content in the hippocampus and prefrontal cortex (PMID 31625062).
• An immunological study examined the influence of Selank on cytokine levels under conditions of "social" stress (PMID 32621722).
• A Russian clinical report examined efficacy and possible mechanisms of Selank as a peptide anxiolytic in the therapy of generalised anxiety disorder and neurasthenia (PMID 18454096).

Cross-reading these papers makes the evidentiary situation clear: Selank has a substantive experimental pharmacology literature and essentially no public physicochemical-stability literature. That asymmetry is common for compounds developed largely outside the FDA and EMA submission pathways, where formal stability dossiers exist as regulatory documents rather than journal articles.

Degradation and safety questions: What Studies Report

A frequent assumption is that degraded peptide is automatically harmful. The indexed Selank literature does not test that proposition — no cited paper administered deliberately degraded or heat-stressed material. What the literature does contain is organ-level safety-adjacent observation under stress models: researchers examined morphological parameters of rat liver during chronic foot-shock stress with Selank (PMID 31243679), and a separate study examined the functional state of rat hepatocytes under restraint stress (PMID 28853100). Both were animal experiments using prepared material, and neither reported on degradation products or on the consequences of storage error.

More generally, peptide degradation in stability science is characterised as loss of potency plus formation of related substances, and the identity and toxicology of those related substances are established separately for each molecule. For Selank, no such characterisation appears in the literature available here.

Regulatory context

Selank is not an FDA-approved drug in the United States; material sold for laboratory work is typically labelled research-use-only, and research-use-only labelling carries no assurance of pharmaceutical-grade stability testing, sterility, or endotoxin control. Clinical investigation has occurred outside the United States, including the Russian report on generalised anxiety disorder and neurasthenia noted above (PMID 18454096). Regulatory approval status and stability documentation are linked: approved products carry stability data reviewed by a regulator, whereas research chemicals generally do not.

Limits of the evidence, stated plainly

1. No Selank stability study was located in the indexed literature — no accelerated-stability, photostability, freeze-thaw or in-use stability report.
2. The pharmacology papers do not fill that gap. Their abstracts describe species, models and outcomes, not vial handling.
3. Class extrapolation is not measurement. Statements about lyophilized versus aqueous stability, temperature dependence and adsorption are general peptide-chemistry principles and may or may not predict Selank's actual behaviour.
4. Structure-based predictions are weak evidence. The absence of cysteine, methionine, tryptophan, asparagine and glutamine reduces the theoretical likelihood of oxidation and deamidation but says nothing quantitative about hydrolysis rates.
5. Analytical context is missing. Without a stated assay and acceptance criterion, a "days" or "weeks" figure for a reconstituted solution has no defined meaning.

Readers comparing claims about Selank storage will find that the confident numbers come from commercial or forum sources, while the peer-reviewed record is silent. Recognising which of those two categories a claim belongs to is the most useful thing this topic offers.

References

• Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity (Protein and Peptide Letters, 2018)
• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons (Bulletin of Experimental Biology and Medicine, 2017)
• Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice (Bulletin of Experimental Biology and Medicine, 2016)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)
• The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (Current Reviews in Clinical and Experimental Pharmacology, 2021)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008)